房颤患者接受PCI的抗栓治疗管理:JACC最新综述
房颤合并卒中风险因素者需口服抗凝(OAC),直接口服抗凝药较维生素K拮抗剂降低颅内出血风险。约5%–10%接受经皮冠状动脉介入(PCI)的患者合并房颤,指南推荐此类患者同时接受双联抗血小板治疗(DAPT),但OAC联合DAPT的三联抗栓治疗增加出血风险。直接口服抗凝药研究显示,OAC联合P2Y12抑制剂的双联抗栓治疗较含维生素K拮抗剂的三联治疗具有更优的安全性。本综述更新该领域证据并讨论未来方向。
要点
- 约5%–10%接受PCI的患者合并房颤,需兼顾卒中预防与缺血并发症预防。
- OAC联合DAPT的三联抗栓治疗较单用OAC或DAPT增加出血风险。
- OAC联合P2Y12抑制剂的双联抗栓治疗较含维生素K拮抗剂的三联治疗安全性更优。
核心结论
- 房颤合并卒中风险因素者需OAC,直接口服抗凝药较维生素K拮抗剂降低颅内出血风险。
- PCI合并房颤患者中,OAC联合P2Y12抑制剂的双联抗栓治疗较含维生素K拮抗剂的三联治疗具有更优的安全性。
研究设计与样本
- 本文为JACC state-of-the-art综述,总结房颤患者接受PCI后抗栓治疗管理的证据。
主要发现
- 约5%–10%接受PCI的患者合并房颤。
- OAC联合DAPT的三联抗栓治疗较单用OAC或DAPT增加出血风险。
- 直接口服抗凝药研究显示OAC联合P2Y12抑制剂的双联抗栓治疗较含维生素K拮抗剂的三联治疗安全性更优。
临床怎么用
- 房颤合并卒中风险因素者应接受OAC以降低卒中或系统性栓塞风险。
- PCI合并房颤患者需权衡卒中预防与缺血并发症预防,关注三联抗栓治疗的出血风险。
- 直接口服抗凝药联合P2Y12抑制剂的双联抗栓治疗可作为较含维生素K拮抗剂三联治疗安全性更优的选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most patients with atrial fibrillation (AF) and risk factors for stroke require oral anticoagulation (OAC) to decrease the risk of stroke or systemic embolism. This is now best achieved with direct oral anticoagulants that decrease the risk of intracranial bleeding compared with vitamin K antagonists. Of note, approximately 5% to 10% of patients undergoing percutaneous coronary intervention have AF, which complicates antithrombotic therapy in daily practice, because the guidelines recommend that these patients also receive dual antiplatelet therapy (DAPT) to reduce the risk of ischemic complications. However, combining OAC with DAPT, a strategy also known as triple antithrombotic therapy, is known to increase the risk of bleeding compared with the use of OAC or DAPT alone. Studies of direct oral anticoagulants are now emerging that show the favorable safety profile of double antithrombotic therapy with OAC and a P2Y12 inhibitor in comparison with triple antithrombotic therapy including the use of vitamin K antagonists. The scope of this review is to provide an update on this topic as well as to discuss future directions in the management of antithrombotic therapy after percutaneous coronary intervention in AF patients requiring chronic OAC.
引用
- Capodanno D, Huber K, Mehran R, et al. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019. PMID: 31272556. doi:10.1016/j.jacc.2019.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。